IGF2 and hepatocellular carcinoma: Several new inhibitors of IGF1 or its receptor are in current clinical trials for HCC, including Octreotide (Novartis), a Somatostatin analog and MEDI 573 (Astrazeneca), targeting either IGF1 and or IGFII, as well as Linsitinib (OSI Pharmaceuticals), Cixutumumab (ImClone), AVE1642 (Sanofi-Aventis), which are IGF receptor antagonists.